By Emily Flitter
NEW YORK (Reuters) - To win a guilty verdict against one of hedge fund titan Steven A Cohen's most senior portfolio managers, U.S. prosecutors face a tough task: convincing a jury that a man who already admitted to breaking the law is telling the truth on the witness stand.
On Friday, U.S. authorities arrested and charged Michael Steinberg, a 16-year veteran of Cohen's $15 billion SAC Capital Advisors, with insider trading in shares of the technology stocks Dell
The case against Steinberg, 40, is built heavily on the testimony of one of his former colleagues, Jon Horvath, who has admitted to insider trading and is now cooperating with the government.
"What they're going to need to prove is that Steinberg got inside information that he knew came from an insider and that he then traded on it," said Marc Greenwald, a former U.S. prosecutor in New York who is now a partner at Quinn Emanuel in New York, and not involved in the case. "It all depends on what Horvath said he said and whether everybody believes him."
A spokeswoman for U.S. Attorney Preet Bharara declined to comment. A spokesman for SAC Capital declined to comment.
Steinberg's lawyer, Barry Berke said after Steinberg's arrest that his client had done "absolutely nothing wrong" and his "trading decisions were based on detailed analysis."
Steinberg could not be reached for comment. Berke did not immediately respond to a request for comment for this article.
The case against Steinberg, one of Cohen's closest confidants, is different from other recent insider trading cases because it relies not so much on incriminating emails or wiretaps but instead on a chain of people who have admitted to passing along inside information.
By contrast, the pending criminal case against Mathew Martoma, a former SAC portfolio manager accused of trading on inside information in two drug stocks, is built on direct communications - including emails and precisely timed phone calls - between Martoma and someone with inside knowledge of the drug companies' business.
There has been widespread talk among defense lawyers familiar with insider trading cases that prosecutors would like Steinberg and Martoma to take pleas and agree to provide incriminating evidence against Cohen, but so far that has not happened. Martoma rejected several attempts by prosecutors to strike a deal before he was indicted, according to people familiar with the matter.
Martoma's lawyer declined to comment.
Court papers filed in the Steinberg case show how people working at Dell and Nvidia fed non-public information about the companies into a ring of hedge fund analysts who - despite working at several different firms - shared it with each other. They were caught in 2011, and the accused either pleaded guilty or were convicted by a jury.
One of the people in the ring was Jesse Tortora, an analyst at Diamondback Capital Management. Tortora passed the non-public information to Horvath, an analyst who reported directly to Steinberg at SAC's unit Sigma Capital.
The five-count indictment alleges Steinberg generated about $1.4 million in illegal profits for Cohen's $15 billion hedge fund. In a related civil complaint against Steinberg, the U.S. Securities and Exchange Commission said the information allowed Steinberg to generate $6.4 million through either profits or avoided losses for the hedge fund.
Emails submitted as evidence in the trials of two of the other hedge fund analysts in the insider ring included Steinberg and Horvath as addressees, and showed Horvath discussing information about Dell that he wrote came "from someone at the company," adding, "please keep to yourself as obviously not well known."
Steinberg later wrote: "Yes normally we would never divulge data like this."
In another email, Horvath wrote exclusively to Steinberg to discuss a position on Dell and warned: "JT asked me specifically to be extra sensitive with the info," in probable reference to Jesse Tortora.
After pleading guilty last year, Horvath began cooperating with government investigators. He told them he gave the inside information to Steinberg, who traded on it, according to Steinberg's indictment. If the case goes to trial, Horvath will have to testify against his former boss.
"I presume he's going to say 'I told (Steinberg) I got it from an insider,'" Greenwald, the former U.S. prosecutor, said.
In response, Greenwald suggested that Steinberg may well say: "Hey I didn't know he got it from an insider, he told me he got it from Dell, I didn't know it was from someone who was breaching his duty, and I made the trades based on a variety of information."
In the weeks leading up to his arrest, Steinberg conveyed confidence, according to people who know him, telling friends he knew he would be indicted but that he expected to beat the charges.
(Reporting By Emily Flitter, additional reporting by Katya Wachtel; Editing by Martin Howell and Chris Reese)
Source: http://news.yahoo.com/analysis-insider-case-against-sac-manager-may-tough-192655088--sector.html
uc berkeley harrison barnes brett ratner stevie nicks anchorman capybara duggars
![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 28-Mar-2013
Share ] 
You wouldn't expect barn-burning multimedia benchmark results from a system with 2GB of memory and an Intel Atom Z2760 processor, but on the flip side the Atom processor is very frugal with battery consumption. The Latitude 10 scored relatively high on CineBench R11.5 (0.55 points), matching the HP Envy X2. It also had one of the better Atom-based scores on our Handbrake video encoding test (6:27). Its 1,291 point score on PCMark 7 was middling, far behind the Microsoft Surface Pro (4,768 points) and its ultrabook-class competitors. Basically, if you need a fast system, go with one of the ultrabook-class slates like the Surface Pro or Acer Iconia W700. 
Reader Ryan Thistle made his home screen a little easier to use with big, tiled icons in a layout similar to the dialer on a phone. Here's how he put it together. 
A blood test that tracks DNA fragments from dying tumor cells may one day be used to monitor how well patients are responding to cancer treatment.